

The text in English is an unofficial translation of the Swedish original wording. If there are differences between the English translation and the Swedish original, the Swedish text takes precedence.

ITEM 13

PROPOSAL BY THE BOARD ON AUTHORIZATION

The Board of Promore Pharma AB (publ) proposes that the general meeting authorizes the Board, on one or several occasions during the period up to the next Annual General Meeting, to resolve upon an issue of new shares, convertible instruments and warrants in accordance with the following.

The Board will be authorized to resolve upon a new issue of shares, convertible instruments and warrants with or without deviation from the shareholders' preferential rights and/or with terms on payment-in-kind, set-off or otherwise with particular terms and conditions.

Upon disapplication from the shareholders' preferential rights, the subscription price will be determined based on the share's, convertible instrument's or warrant's market value at the time of each issue, and where applicable be subject to an issue discount at market rate.

The total number of shares to be issued, shares pursuant to convertible instrument and shares pursuant to warrants will be not more than 12,142,787 new shares, corresponding to a dilution of approximately 20 per cent.

The purpose of the proposal and the possibility of disapplication from the shareholders' preferential rights, is to increase the flexibility in acquisitions or capital raising.

The Board, or any person appointed by the Board, is authorized to make any minor adjustments to the resolution which may be required in conjunction with the registration with the Swedish Companies Office or because of other formal requirements.

A valid resolution in accordance with the Board's proposal requires that the proposal be approved by shareholders representing at least two thirds of both the votes cast as well as the shares represented at the meeting.

Solna April 2022

Promore Pharma AB (publ)

Board of Directors